Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Nordic drugmaker Swedish Orphan Biovitrum saw its shares rise 7.05% to 170.15 Swedish kronor this morning, after it announced strong first-quarter 2018 results. 26 April 2018
The first quarter 2018 financial results of UK drugmaker GlaxoSmithKline have been hit by the resurgence of the pound, with shares in the company falling sharply after the figures were announced. 25 April 2018
Western pharmaceutical companies do not plan to reduce their presence in the Russian market due to a recent deterioration of business climate in the country, caused by a new package of Western sanctions, according to the companies and the Russian Ministry of Health, reports The Pharma Letter’s Russian correspondent. 25 April 2018
Family-owned German pharma Boehringer Ingelheim today presented its latest pipeline updates at a R&D press conference titled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim. 25 April 2018
US obesity-focused biopharma company Orexigen Therapeutics (Nasdaq: OREX) has entered into an asset purchase agreement with Nalpropion Pharmaceuticals to sell substantially all of the assets of the company, subject to court approval. 25 April 2018
Reda Guiha, regional president of international developed markets for Pfizer Vaccines, writes a topical Expert View piece timed to coincide with World Immunization Week. 25 April 2018
The Russian national Parliament (State Duma) plans to consider the possibility of introducing a ban on the imports of drugs from the USA and some European Union states to Russia at the beginning of the current year, according to Duma press-service. 25 April 2018
After a four-week courtship and four rebuttals, Shire has finally succumbed to Takeda Pharmaceutical’s fifth offer to acquire the Ireland-based rare diseases company. 25 April 2018
The week started badly for Eli Lilly with a potential setback in its hopes to gain US approval for baricitinib in rheumatoid arthritis, but things took a turn for the better on Tuesday with the presentation of the company’s financial results for the first quarter of 2018. 24 April 2018
Mid-afternoon on Tuesday, a tersely-worded statement from takeover target Shire revealed the London-listed firm had received a fifth offer from Takeda Pharmaceutical. 24 April 2018
Japanese drug major Astellas Pharma today announced that, on March 23, it submitted a New Drug Application (NDA) for marketing approval of gilteritinib in Japan for the treatment of adult patients with FLT3 mutation-positive (FLT3mut+) relapsed or refractory acute myeloid leukemia (AML). 24 April 2018
The rising cost of drug development, growing need for medicines with an aging population and the greater prevalence of chronic conditions, political uncertainty – many factors suggest that the problem of pricing drugs affordably is not about to away any time soon. 24 April 2018
The advisory panel of the US Food and Drug Administration has delivered a mixed verdict on Eli Lilly and Incyte’s experimental rheumatoid arthritis therapy baricitinib, backing the use of the drug at a lower dose, while raising safety concerns over its use at higher dosage levels. 24 April 2018
Highlighting the enormous burden of migraine in the UK, a new report – titled Society's headache: the socioeconomic impact of migraine - will be launched today in the Houses of Parliament. 24 April 2018